Relief Therapeutics Holding Bilan de santé

Santé financière contrôle des critères 5/6

Relief Therapeutics Holding possède un total de capitaux propres de CHF49.3M et une dette totale de CHF12.0K, ce qui porte son ratio d'endettement à 0.02%. Son actif total et son passif total sont CHF70.9M et de CHF21.7M.

Informations clés

0.02%

Ratio d'endettement

CHF 12.00k

Dette

Ratio de couverture des intérêts	n/a
Argent liquide	CHF 10.73m
Fonds propres	CHF 49.27m
Total du passif	CHF 21.65m
Total des actifs	CHF 70.92m

Mises à jour récentes de la santé financière

Pas de mise à jour

Recent updates

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de 0QKQ ( CHF14.7M ) dépassent ses passifs à court terme ( CHF4.8M ).

Passif à long terme: Les actifs à court terme de 0QKQ ( CHF14.7M ) ne couvrent pas ses passifs à long terme ( CHF16.9M ).

Historique et analyse du ratio d'endettement

Niveau d'endettement: 0QKQ dispose de plus de liquidités que de sa dette totale.

Réduire la dette: Le ratio d'endettement de 0QKQ a été réduit de 6.6% à 0.02% au cours des 5 dernières années.

Bilan

Analyse des pistes de trésorerie

Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.

Piste de trésorerie stable: 0QKQ dispose d'une piste de trésorerie suffisante pour plus de 3 ans sur la base de son flux de trésorerie disponible actuel.

Prévisions de trésorerie: 0QKQ dispose d'une marge de trésorerie suffisante pour 1 ans si le flux de trésorerie disponible continue de diminuer à un taux historique de 21.2 % chaque année.

Relief Therapeutics Holding Bilan de santé

Santé financière contrôle des critères 5/6

Informations clés

Mises à jour récentes de la santé financière

Recent updates

Relief Therapeutics Announces Positive Final Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa

Renexxion, LLC signed a letter of intent to acquire Relief Therapeutics Holding SA (SWX:RLF) in a reverse merger transaction valued at $260 million.

Relief Therapeutics Reports New Study Results for RLF-OD032 and Files Provisional Patents

Relief Therapeutics Holding SA Announces Promising Preliminary Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa

Relief Therapeutics Holding SA Reports Positive Results from RLF-OD032 Proof-of-Concept Clinical Study for Phenylketonuria

Relief Therapeutics Completes Clinical Phase in RLF-OD032 Proof-Of-Concept Study; Topline Results Expected in October 2024

New minor risk - Shareholder dilution

New major risk - Share price stability

Relief Therapeutics Holding SA Announces PKU GOLIKE Study Results Presentation at SSIEM 2024

Relief Therapeutics Holding SA to Report First Half, 2024 Results on Aug 30, 2024

Relief Therapeutics Holding Announces Michelle Lock Will Not Stand for Re-Election as A Member of the Board of Directors

Relief Therapeutics Holding SA, Annual General Meeting, Jun 27, 2024

Relief Therapeutics Announces Executive Changes

Full year 2023 earnings released: CHF8.35 loss per share (vs CHF4.81 loss in FY 2022)

New minor risk - Financial data availability

Relief Therapeutics Holding SA announced that it expects to receive CHF 50 million in funding from Global Emerging Markets and another investor

Relief Therapeutics Holding SA announced that it expects to receive CHF 50 million in funding from Global Emerging Markets and another investor

New minor risk - Share price stability

Less than half of directors are independent

Relief Therapeutics Holding Sa Announces CEO Changes

First half 2023 earnings released: CHF5.10 loss per share (vs CHF2.55 loss in 1H 2022)

New major risk - Financial position

Relief Therapeutics Holding AG announced that it expects to receive CHF 5 million in funding

New major risk - Share price stability

Relief Therapeutics Holding AG, Annual General Meeting, Jun 20, 2023

Relief Therapeutics Announces Enrollment of First Three Patients in Proof-Of-Concept Clinical Trial of Rlf-Td011 for the Treatment of Epidermolysis Bullosa

RELIEF THERAPEUTICS Holding SA Announces IRB Approval of Investigator-Initiated Trial Evaluating RLF-TD011 as an Adjunctive Treatment for Cutaneous T-Cell Lymphom

Acer Therapeutics and Relief Therapeutics Announce U.S. FDA Approval of Olpruva™ for Patients with Urea Cycle Disorders

Relief Therapeutics Holding AG (SWX:RLF) acquired ZYESAMI of NRx Pharmaceuticals, Inc.

Relief Therapeutics Holding AG and NRx Pharmaceuticals, Inc. Announces Close of Definitive Settlement Agreements

Relief Therapeutics Holding AG Appoints Jeremy Meinen as Chief Financial Officer

No independent directors

Relief Therapeutics Holding AG Announces Six-Month Stability Data on a New Formulation of RLF-100 (Aviptadil)

RELIEF THERAPEUTICS Holding SA Promotes Paolo Galfetti to Chief Operating Officer

Relief Therapeutics Holding SA Announces U.S. Launch of PKU GOLIKE

Relief Therapeutics Holding AG Announces IRB Approval and Initiation of an Investigator Initiated Trial of Nexodyn for Epidermolysis Bullosa At Ann & Robert H. Lurie Children's Hospital of Chicago

Relief Therapeutics Holding AG has filed an IPO.

Relief Therapeutics Holding AG and NRx Pharmaceuticals, Inc. Announce Tentative Settlement of Pending Litigation

Relief Therapeutics Holding SA Appoints David McCullough as Head of U.S. Market Access, Effective August 22, 2022

RELIEF THERAPEUTICS Holding SA and Acer Therapeutics Inc. Announce That the European Commission Has Granted Orphan Drug Designation for Acer-001 in Maple Syrup Urine Disease

Relief Therapeutics Holding Ag Announces U.S. Food and Drug Administration Accepts for Review Acer’s Resubmitted New Drug Application

Acer Therapeutics and Relief Therapeutics Announce FDA Acceptance for Review of NDA Resubmission for ACER-001 for Treatment of UCDs

Relief Therapeutics Appoints Serene Forte, Ph.D., MPH, as Senior Vice President, Head of Genetic Medicine

Acer Therapeutics and Relief Therapeutics Announce Update on U.S. FDA Review of New Drug Application for ACER-001

Relief Therapeutics Expands U.S. Commercial Team

Acer Therapeutics Inc. and Relief Therapeutics Holding AG Announce Presentation of Acer-001 Data At the Genetic Metabolic Dieticians International Conference

Relief Therapeutics Holding AG, Annual General Meeting, May 31, 2022

No independent directors

Relief Therapeutics Holding AG Appoints Drew Cronin-Fine as Executive Director, Head of U.S. Marketing

Acer Therapeutics Inc. and Relief Therapeutics Announce Presentation of ACER-001 Data at the Society for Inherited Metabolic Disorders Annual Meeting

Relief Therapeutics Holding SA Files Trademark Application for RLF-100 with the U.S. Patent and Trademark Office

Relief Therapeutics Holding AG Approves Election of Michelle Lock as New Member of the Board of Directors

NRx Pharmaceuticals Files Counterclaim Against its Former Collaboration Partner, Relief Therapeutics

Relief Therapeutics Reports Successful Conclusion of Patent Examination Procedure for Patent Application Entitled, 'Vasoactive Intestinal Peptide (VIP) for the Use in the Treatment of Drug-Induced Pneumonitis

Relief Therapeutics Holding SA Announces New Safety Update on Aviptadil

Chief Commercial Officer Christiaan L. J. Stijnen has left the company

Relief Therapeutics Holding AG (SWX:RLF) completed the acquisition of APR Applied Pharma Research s.a.

Acer Therapeutics Plans NDA Submission for Acer-001 in Third Quarter 2021 Following Pre-NDA Meeting with FDA

Relief Provides Update on Progress and Plans with Acer-001 for the Treatment of Urea Cycle Disorders

Relief Therapeutics Holding AG (SWX:RLF) signed binding term sheet to acquire APR Applied Pharma Research s.a. for CHF.

Relief Therapeutics Successfully Demonstrated Ten-Day Accelerated Recovery from Respiratory Failure Among Critically Iii Patients with Covid-19

NeuroRx and Relief Therapeutics Holding AG Report Initial Phase 2b/3 Study Results Demonstrating Significant Benefit of ZYESAMI™ in Reducing Hospital Stay Among Patients with Respiratory Failure due to Critical COVID-19

Director has left the company

RELIEF THERAPEUTICS Holding AG Announces Resignation of Thomaz Burckhardt as Member of the Board of Directors

Relief Therapeutics Holding AG Affirms Initiation of Phase 2/3 Trial of Inhaled RLF-100(TM) (Aviptadil; ZYESAMI(TM)) in Severe COVID-19 Patients

Relief Therapeutics Holding Ag and Acer Therapeutics Inc. Announces the Companies Have Signed an Option Agreement

Relief Therapeutics Holding AG (SWX:RLF) signed a binding term sheet to acquire AdVita Lifescience GmbH for €45 million.

Analyse de la situation financière

Historique et analyse du ratio d'endettement

Bilan

Analyse des pistes de trésorerie

Découvrir des entreprises saines